File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: A multicentric study of netilmicin once daily versus thrice daily in patients with appendicitis and other intra-abdominal infections

TitleA multicentric study of netilmicin once daily versus thrice daily in patients with appendicitis and other intra-abdominal infections
Authors
Issue Date1989
PublisherOxford University Press. The Journal's web site is located at http://jac.oxfordjournals.org/
Citation
Journal Of Antimicrobial Chemotherapy, 1989, v. 23 n. 5, p. 773-783 How to Cite?
AbstractThis multicentric, randomized, double-blind trial compared the efficacy and safety of netilmicin, 4.5 mg/kg od and 1.5 mg/kg tid, in patients with intra-abdominal infections. Of 114 patients enrolled, 57 patients (mean age 40.3 years) in the od group and 55 (mean age 36.8 years) in the tid group were evaluated for efficacy; 58 and 56 patients in corresponding groups were evaluated for safety. Among those evaluated for efficacy were 12 od-treated and 11 tid-treated patients with documented septicaemia, and 32 and 30 patients of respective groups with polymicrobial infections. Initially, 86 and 81 netilmicin-susceptible causative microorganisms were isolated in corresponding groups. Of these pathogens, 55% in the od group and 62% in the tid group were Escherichia coli. Daily dosage of netilmicin ranged from 3.70 to 4.71 mg/kg (mean 4.50) for the od group and from 3.06 to 4.76 mg/kg (mean 4.46) for the tid group. Duration of netilmicin therapy ranged from six to 13 days (mean 8.7 days) for od-treated patients and from seven to 16 days (mean 8.8 days) for tid-treated patients. Concomitant metronidazole was administered to 41 patients of the od group and 34 of the tid group; one patient in the tid group received clindamycin. Clinical and bacteriological responses were assessed, and peak and trough serum netilmicin levels were measured periodically during therapy. Laboratory tests, including determinations of serum creatinine and blood urea nitrogen values, were performed throughout the trial. A clinical cure was achieved in 57/57 od-treated patients and 54/55 tid-treated patients; treatment failed in one tid-treated patient (1/55). In od and tid groups, 86/86 and 80/81 netilmicin-susceptible pathogens initially isolated were considered to be eliminated, respectively; one isolate (Esch. coli) persisted in the tid group. Mean peak serum netilmicin concentration in the od group was approximately two-fold greater than that in the tid group; mean trough serum netilmicin concentrations were similar for the two groups. Adverse reactions were limited to mild pain at the site of netilmicin administration in several patients in each treatment group. Netilmicin od and tid (alone or in combination with metronidazole) were similarly efficacious in the treatment of patients with appendicitis and other intra-abdominal infections caused by netilmicin-susceptible pathogens. Both dosage regimens of netilmicin were safe and well tolerated.
Persistent Identifierhttp://hdl.handle.net/10722/172594
ISSN
2015 Impact Factor: 4.919
2015 SCImago Journal Rankings: 2.157
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorHollender, LFen_US
dc.contributor.authorBahnini, Jen_US
dc.contributor.authorDe Manzini, Nen_US
dc.contributor.authorLau, WYen_US
dc.contributor.authorFan, STen_US
dc.contributor.authorHermansyur, Ken_US
dc.contributor.authorBenny, Pen_US
dc.contributor.authorHusni, ANen_US
dc.contributor.authorSutjiptoen_US
dc.contributor.authorLorber, RRen_US
dc.date.accessioned2012-10-30T06:23:37Z-
dc.date.available2012-10-30T06:23:37Z-
dc.date.issued1989en_US
dc.identifier.citationJournal Of Antimicrobial Chemotherapy, 1989, v. 23 n. 5, p. 773-783en_US
dc.identifier.issn0305-7453en_US
dc.identifier.urihttp://hdl.handle.net/10722/172594-
dc.description.abstractThis multicentric, randomized, double-blind trial compared the efficacy and safety of netilmicin, 4.5 mg/kg od and 1.5 mg/kg tid, in patients with intra-abdominal infections. Of 114 patients enrolled, 57 patients (mean age 40.3 years) in the od group and 55 (mean age 36.8 years) in the tid group were evaluated for efficacy; 58 and 56 patients in corresponding groups were evaluated for safety. Among those evaluated for efficacy were 12 od-treated and 11 tid-treated patients with documented septicaemia, and 32 and 30 patients of respective groups with polymicrobial infections. Initially, 86 and 81 netilmicin-susceptible causative microorganisms were isolated in corresponding groups. Of these pathogens, 55% in the od group and 62% in the tid group were Escherichia coli. Daily dosage of netilmicin ranged from 3.70 to 4.71 mg/kg (mean 4.50) for the od group and from 3.06 to 4.76 mg/kg (mean 4.46) for the tid group. Duration of netilmicin therapy ranged from six to 13 days (mean 8.7 days) for od-treated patients and from seven to 16 days (mean 8.8 days) for tid-treated patients. Concomitant metronidazole was administered to 41 patients of the od group and 34 of the tid group; one patient in the tid group received clindamycin. Clinical and bacteriological responses were assessed, and peak and trough serum netilmicin levels were measured periodically during therapy. Laboratory tests, including determinations of serum creatinine and blood urea nitrogen values, were performed throughout the trial. A clinical cure was achieved in 57/57 od-treated patients and 54/55 tid-treated patients; treatment failed in one tid-treated patient (1/55). In od and tid groups, 86/86 and 80/81 netilmicin-susceptible pathogens initially isolated were considered to be eliminated, respectively; one isolate (Esch. coli) persisted in the tid group. Mean peak serum netilmicin concentration in the od group was approximately two-fold greater than that in the tid group; mean trough serum netilmicin concentrations were similar for the two groups. Adverse reactions were limited to mild pain at the site of netilmicin administration in several patients in each treatment group. Netilmicin od and tid (alone or in combination with metronidazole) were similarly efficacious in the treatment of patients with appendicitis and other intra-abdominal infections caused by netilmicin-susceptible pathogens. Both dosage regimens of netilmicin were safe and well tolerated.en_US
dc.languageengen_US
dc.publisherOxford University Press. The Journal's web site is located at http://jac.oxfordjournals.org/en_US
dc.relation.ispartofJournal of Antimicrobial Chemotherapyen_US
dc.subject.meshAbdomenen_US
dc.subject.meshAdolescenten_US
dc.subject.meshAdulten_US
dc.subject.meshAgeden_US
dc.subject.meshAged, 80 And Overen_US
dc.subject.meshAppendicitis - Drug Therapyen_US
dc.subject.meshBacterial Infections - Drug Therapy - Microbiologyen_US
dc.subject.meshClinical Trials As Topicen_US
dc.subject.meshDouble-Blind Methoden_US
dc.subject.meshFemaleen_US
dc.subject.meshHumansen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshMulticenter Studies As Topicen_US
dc.subject.meshNetilmicin - Administration & Dosage - Pharmacokinetics - Therapeutic Useen_US
dc.subject.meshRandom Allocationen_US
dc.titleA multicentric study of netilmicin once daily versus thrice daily in patients with appendicitis and other intra-abdominal infectionsen_US
dc.typeArticleen_US
dc.identifier.emailFan, ST: stfan@hku.hken_US
dc.identifier.authorityFan, ST=rp00355en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1093/jac/23.5.773-
dc.identifier.pmid2668247-
dc.identifier.scopuseid_2-s2.0-0024377839en_US
dc.identifier.volume23en_US
dc.identifier.issue5en_US
dc.identifier.spage773en_US
dc.identifier.epage783en_US
dc.identifier.isiWOS:A1989U688600014-
dc.publisher.placeUnited Kingdomen_US
dc.identifier.scopusauthoridHollender, LF=7102416282en_US
dc.identifier.scopusauthoridBahnini, J=6603951346en_US
dc.identifier.scopusauthoridDe Manzini, N=7003830806en_US
dc.identifier.scopusauthoridLau, WY=7402933199en_US
dc.identifier.scopusauthoridFan, ST=7402678224en_US
dc.identifier.scopusauthoridHermansyur, K=6504507524en_US
dc.identifier.scopusauthoridBenny, P=36509892200en_US
dc.identifier.scopusauthoridHusni, AN=6507504226en_US
dc.identifier.scopusauthoridSutjipto=7409902521en_US
dc.identifier.scopusauthoridLorber, RR=6701428530en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats